Product for Out-Licensing
- Overview
- Product Profile
- Data
Microcaps® Theophylline ER
Designed to reduce the high drug concentrations associated with traditional theophylline formulations, Eurand’s sustained-release formulations can decrease incidence of patient side effects.
Eurand’s Microcaps technology utilizes a proprietary microencapsulation technique that taste-masks even the most bitter drug particles, ensuring a pleasant taste and smooth mouthfeel.
Therapeutic Category |
Respiratory |
Indication |
|
Development Status |
Commercialized; Licensing opportunities available |
Available Dosage Strength(s) |
|
Product Description |
Sustained-release capsule |
Eurand Technology |
Microcaps® - Taste-masking technology |
Licensing Opportunities |
Eurand is seeking licensing partners for global opportunities. |
Successfully commercialized for more than 30 years.
This information is provided solely for the purpose of the evaluation of business opportunities by potential collaboration partners. The information is based on currently existing data and marketing authorizations in a number of jurisdictions and should not be assumed to be approved by regulatory authorities in any individual country. Consumers should consult with their individual physician for product information and should not rely upon any information provided here.
For more information on this product, please contact Eurand.